Adicet Bio initiates Phase I/II trial of ADI-212, an allogeneic gamma delta CAR-T therapy for metastatic castration-resistant ...
Qure submits BLA for AMT-130, first gene therapy seeking accelerated FDA approval for Huntington's disease treatment. Learn ...
Seoul National University researchers develop breakthrough prime editing platform for genomic DNA integration up to 6.5kb ...
NYM032, a domestically developed PSMA-targeted radioligand therapy, into pivotal Phase III testing for metastatic ...
Boston Children's Hospital secures $3.9M NIH grant to develop new treatments for endometriosis pain using lipid receptors. Discover breakthrough research.
CytoDyn closes $16.5M financing to advance leronlimab development across colorectal cancer and oncology indications. Clinical trials accelerated.
Vincere Biosciences receives $1.3M NIDDK SBIR Phase II grant for USP30 inhibitor IND-enabling studies in acute kidney injury treatment. Learn more.
GentiBio receives $1.07M NIH grant for engineered Treg therapy in type 1 diabetes. Discover breakthrough in allogeneic cell therapy treatment.
Typewriter Therapeutics secures $56M Series A to develop in vivo CAR T gene therapy using non-viral RNA platform. Discover the breakthrough.
Biocytogen licenses fully human VHH antibody from RenNano platform to Qilu Pharmaceutical for neuroscience drug development. Discover the partnership details.
Keymed Biosciences licenses IL-4Rα antibody stapokibart to Aeira for 18 emerging markets in Southeast and Central Asia. Discover the expansion details.
Boehringer Ingelheim partners with Owkin to license K Pro AI platform and immunology data. Third top-10 pharma deal in four months. Learn more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results